Valproate lowers plasma concentration of olanzapine [2]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 432-434

  Bergemann, Niels ^a   Kress, Kai R ^a   Abu Tair, Fatima ^a   Frick, Alex ^a   Kopitz, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENPERIDOL; BIPERIDEN; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; LORAZEPAM; OLANZAPINE; VALPROIC ACID; ZIPRASIDONE;

ADULT; BLOOD SAMPLING; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; LETTER; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; REMISSION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MOOD DISORDERS; VALPROIC ACID;

EID: 33746880605     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000227353.46450.52     Document Type: Letter

References (21)

1. Ereshefsky L. Pharmokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry. 1996;57(suppl 11):12-25.
2. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit. 1999;21:87-90.
3. Rao ML, Hiemke C, Grasmäder K, et al. Olanzapin: pharmakologie, pharmakokinetik und therapeutisches drug monitoring. Fortschr Neurol Psychiatr. 2001;69:510-517.
4. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37:63-68.
5. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull. 2003;37(suppl 2):74-88.
6. Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
7. Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1995;668:85-90.
8. Chiu JA, Franklin RB. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J Pharm Biomed Anal. 1996;14:609-615.
9. Aravagiri M, Ames D, Wirshing WC, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit. 1997;19:307-313.
10. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM Expert Group Consensus Guidlines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
11. Gaertner I, Gaertner HJ, Vontheim R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21:305-310.
12. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281-298.
13. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996; 57:40-52.
14. Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen: UNI-MED; 1999.
15. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
16. Kassahun K, Mattiuz E, Nyhart E Jr. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81-93.
17. Shirley KL, Hon YY, Penzak SR, et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology. 2003;28:961-966.
18. Perruca E. Pharmacological and therapeutic properties of valproate: a summary of 35 years of clinical experience. CNS Drugs. 2002;16:695-714.
19. Rogiers V, Akrawi M, Vercruyse A, et al. Effects of the anticonvulsant valproate on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases. Eur J Biochem. 1995;231:337-343.
20. Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs. Clin Pharmacokinet. 1996;31:470-493.
21. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28:99-112.